Ricky Wirawan

Dr. Ricky Wirawan

Department of Pharmacy, Center for Drug Research, Ludwig-Maximilians-Universität München, Munich, Bavaria, Germany
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 August 2025 in RSC Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
RWRicky Wirawan
Ricky Wirawan
MFMatthias Frei
Matthias Frei
AHAnna Heider
Anna Heider
NPNiklas Papenkordt
Niklas Papenkordt
FFFlorian Friedrich
Florian Friedrich
Franz BracherFranz Bracher
Franz Bracher
The duality of halogen-bonding-mediated ligand stabilization and the inteference of NAD + co-factor binding represents an effective strategy in the development of highly potent SIRT2 inhibitors.

7 January 2021 in Synthesis
Verified
Journal Article
Closed access
PDF file
Franz BracherFranz Bracher
Franz Bracher
CGCarina Glas
Carina Glas
RWRicky Wirawan
Ricky Wirawan
N-Aryl-1,2,3,4-tetrahydroisoquinolines are obtained via a convenient and short protocol with a broad range of substituents on both aromatic rings and high functional group tolerance. Starting from readily available ortho-brominated aromatic aldehydes and primary aromatic amines, condensation of these building blocks under reductive conditions gives N-aryl 2-bromobenzylamines. The C-3/C-4-unit of the tetrahydroisoquinoline is introduced using commercially available 2-ethoxyvinyl pinacolboronate under Suzuki conditions. Finally, the obtained crude ortho-ethoxyvinyl benzylamines are cyclized via an intramolecular reductive amination using the combination of triethylsilane/TFA to give the desired N-aryl-1,2,3,4-tetrahydroisoquinolines.

Verified
Journal Article
Open access
PDF file
MFMatthias Frei
Matthias Frei
RWRicky Wirawan
Ricky Wirawan
TWThomas Wein
Thomas Wein
Franz BracherFranz Bracher
Franz Bracher
Selective and potent inhibitors of the NAD+-dependent deacetylase Sirt2 represent a valuable epigenetic strategy for the treatment of currently incurable diseases such as Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, and multiple sclerosis. Guided by molecular docking and MM/GBSA validation studies, a lead structure-based hybridization strategy was developed, resulting in a series of very effective Sirt2 inhibitors. With RW-93, we present a highly potent and subtype selective Sirt2 inhibitor (IC50 = 16 nM), which as a next generation SirReal-type inhibitor significantly surpasses established Sirt2 inhibitors and contributes to the extension of the current SAR profile. The structural modification strategy employed in this study proved to be highly promising, resulting in the identification of the most potent low-molecular-weight Sirt2 inhibitor reported to date, providing a promising target for further medicinal chemistry-driven SAR studies.

12 May 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
MFMatthias Frei
Matthias Frei
RWRicky Wirawan
Ricky Wirawan
TWThomas Wein
Thomas Wein
Franz BracherFranz Bracher
Franz Bracher
Selective and potent inhibitors of the NAD+-dependent deacetylase Sirt2 represent a valuable epigenetic approach for the treatment of hitherto incurable diseases such as Parkinson's disease, Huntington’s disease, Alzheimer's disease and multiple sclerosis. Guided by docking studies, a lead structure-based hybridization concept was developed, resulting in a series of very effective Sirt2 inhibitors. With RW-93 we present a highly potent and selective Sirt2 inhibitor (IC50 = 16 nM), which as a next generation SirReal-type inhibitor significantly surpasses established Sirt2 inhibitors and extends current structure-activity relationships. The structural modification strategy employed in this study proved to be a highly promising approach, resulting in the identification of the most potent low-molecular Sirt2 inhibitors reported to date.

20 September 2025 in Molecules
Verified
Journal Article
Open access
PDF file
RWRicky Wirawan
Ricky Wirawan
SHSimon Huber
Simon Huber
TWThomas Wein
Thomas Wein
Franz BracherFranz Bracher
Franz Bracher
Sirtuin 5 is an NAD+-dependent lysine deacylase that is involved in various biological processes and has emerged as a promising target for pharmaceutical therapies. The development of highly potent and subtype-selective sirtuin 5 inhibitors for their application as chemical tools and drug candidates still poses a significant challenge. Based on our own optimized balsalazide-derived sirtuin 5 inhibitors, this work presents a systematic investigation of the inhibitory effects of derivatives with moieties that were guided by docking experiments to target the nicotinamide ribose vicinal hydroxy groups of the essential co-factor NAD+ via reversible covalent binding to potentially enhance their potency. Our results show that functionalizations with these moieties were tolerated to some extent and possessed a distinct stereo-selective preference. The (S)-configured cyanomethyl derivative 50 with an IC50 of 27 µM emerged from our synthesized library of compounds as the most potent functionalized inhibitor and lies in a similar potency range to other established sirtuin 5 inhibitors. Our findings offer a deeper insight into the structure–activity relationships of our balsalazide-derived heterotriaryl-based sirtuin 5 inhibitors and thus could provide an avenue for further optimizations in the future.